TY - JOUR
T1 - Cost-utility analysis of vaccination against HPV in Israel
AU - Ginsberg, Gary Michael
AU - Fisher, Menachem
AU - Ben-Shahar, Inbar
AU - Bornstein, Jacob
PY - 2007/9/17
Y1 - 2007/9/17
N2 - Using WHO-CHOICE methodology, we calculated cost-utility ratios for various interventions (PAP smear, HPV-DNA testing, VIA and vaccination against HPV) at various frequencies to reduce the burden of cervical cancer and condyloma (in the case of the HPV vaccination) in Israel, which has a low prevalence of cervical cancer. Assuming non-waning efficacy, HPV vaccinations will become cost-effective, very cost-effective and cost saving when the cost per dose falls below $96.85, $50.42 and $27.20, respectively. Attempts should be made to raise compliancy with PAP smears from the current opportunistic 12.2-20.0% per annum either before and/or after the vaccination is introduced.
AB - Using WHO-CHOICE methodology, we calculated cost-utility ratios for various interventions (PAP smear, HPV-DNA testing, VIA and vaccination against HPV) at various frequencies to reduce the burden of cervical cancer and condyloma (in the case of the HPV vaccination) in Israel, which has a low prevalence of cervical cancer. Assuming non-waning efficacy, HPV vaccinations will become cost-effective, very cost-effective and cost saving when the cost per dose falls below $96.85, $50.42 and $27.20, respectively. Attempts should be made to raise compliancy with PAP smears from the current opportunistic 12.2-20.0% per annum either before and/or after the vaccination is introduced.
KW - Cervical cancer
KW - Cost-utility analysis
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=34548319218&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2007.07.018
DO - 10.1016/j.vaccine.2007.07.018
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 17706844
AN - SCOPUS:34548319218
SN - 0264-410X
VL - 25
SP - 6677
EP - 6691
JO - Vaccine
JF - Vaccine
IS - 37-38
ER -
